As 2018 begins, John McCamant, editor of Medical Technology Stock Letter, reviews several 2017 top performers, discusses the turnaround at the FDA, and profiles one company with an innovative non-statin LDL cholesterol in the pipeline.
November 17, 2016 Opinion : 10 biotech companies ripe for a buyout, courtesy of Donald Trump (11-17-16) The Republican sweep of Washington has generated a ton of enthusiasm for biotech stocks. They’re up 10% to 15% since the elections. As a result, biotech analysts’ phones are ringing off the hook again after a depressingly bleak […]
Sentiment – A Core MTSL Investment Methodology February 19, 2015 The most recent reading of the CNN/Money Fear and Greed Indicator has entered the “Extreme Greed” range. While very short-term in nature, it represents the level of expectations investors have in stocks and today that level is quite high. It all suggests that while stocks may […]